Initial management and investigations in acute exacerbation of chronic obstructive pulmonary disease: an audit

C. J. Lawson
Emergency Department, Noble’s Hospital, Isle of Man
courtney.j.lawson@doctors.org.uk

Abstract

Introduction Chronic obstructive pulmonary disease (COPD) affects three million people in England and Wales, including more than 5% of the over 65s. It is the country’s fifth biggest killer, at 30,000 deaths per year. Severe exacerbations are the second commonest cause of emergency admissions, with 15% three-month mortality.

Methods The clinical practice of the Emergency Department (ED) on the Isle of Man was compared with UK best-practice guidelines regarding the initial management and investigations in acute exacerbation of COPD (AECOPD). The National Institute for Health and Care Excellence (NICE) CG101 provides guidance for managing AECOPD. The evidence underpinning these guidelines was appraised and a retrospective audit of 40 patients in the ED was conducted.

Results Compliance to the use of air-driven nebulisers was uncertain due to insufficient documentation. Adequate arterial blood gas (ABG): 19 (47.5%). Chest radiograph (CXR): 39 (97.5%). Electrocardiogram (ECG): 37 (92.5%). Full blood count (FBC) plus urea and electrolytes (U&Es): 38 (95%). All pyrexial patients received blood cultures. Documentation of theophylline use was poor and patients on theophylline did not have levels measured.

Conclusions The initial management and investigations of AECOPD in the ED could be improved through research on nebuliser use, better documentation and implementation of departmental guidance for clinical decision-making.
Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the airways characterised by airflow obstruction. The disease manifests as small-airway inflammation and damaged lung parenchyma with loss of elastic recoil. Most cases are attributed to cigarette smoking and the disease presents with varying severity. The prevalence in England and Wales is estimated at three million and the disease affects more than 5% of the over 65s.\(^1,2\) The yearly mortality is 30,000; COPD is the country’s fifth biggest killer.\(^3\)

The most common symptoms of COPD are a productive cough, dyspnoea and chest tightness.\(^2\) Exacerbations represent an acute worsening of symptoms. Severe exacerbations require hospitalisation and are the second most common cause of emergency admissions in England, with 15% of patients dying within three months of admission. The number of deaths attributed to respiratory disease is nearly double the EU average.\(^1,3\)

The Isle of Man is a British Crown dependency located in the Irish Sea with a population of approximately 85,000. Demographically, 95.6% of the population is Caucasian, life expectancy is 81 years and almost 20% of the population is aged 65 and over.\(^4\)

The jurisdiction of the National Institute for Health and Care Excellence (NICE) does not include the Isle of Man Emergency Department (ED). The ED does not have independent guidelines on managing acute exacerbation of COPD (AECOPD), therefore practice will be compared to the latest UK guidance, *NICE Clinical Guideline 101* (June 2010).\(^5\) This was used to form the audit standards for the initial management and investigations in AECOPD:

- Nebulised pharmaceutical therapy must be prescribed driven by compressed air, not oxygen
- All patients must receive arterial blood gases (ABGs) with the fraction of inspired oxygen (FiO2) noted
- All patients must receive a plain chest radiograph (CXR)
- All patients must receive an electrocardiogram (ECG)
- All patients must receive full blood count (FBC) and renal function test (U&Es)
- Pyrexial patients must have blood cultures taken
- Patients on theophylline must have levels recorded at admission.

The target compliance was 100%, to reflect the guidance.

High-dose oxygen, including nebulised pharmaceutical therapy, can cause unpredictable hypercapnia in patients with AECOPD. Some patients are prone to repeated episodes of hypercapnic respiratory failure, whereas others are unaffected. Oxygen therapy controlled at a target of 88–92%
saturation pending ABGs is therefore recommended to reduce this risk. Patients with a history of hypercapnic respiratory failure should carry an ‘oxygen alert card’ stipulating that nebulisers be air-driven. If compressed air is unavailable, oxygen-driven nebulisers should be limited to six minutes. The implications of oxygen exposure through nebuliser use are underestimated in clinical practice. Oxygen should be administered via nasal cannulae if required simultaneously with nebulisers. The FiO2 using this method is relatively high, so patients with AECOPD may still be at risk of hypercapnic respiratory failure. Air-driven nebulisers should always be preferred and nasal oxygen should only be supplied where clinically necessary.

Arterial blood gas tensions can have high prognostic predictive value in AECOPD. The partial pressure of carbon dioxide (PaCO2) calculated from arterial blood is an independent predictor of short-term mortality in AECOPD. Acidosis is also a predictor of mortality in AECOPD. Hypercapnia is an independent risk factor for predicting mortality. There is good agreement for pH values between arterial and venous samples in patients with COPD; however, this does not apply for measurements of PaO2 or PaCO2. FiO2 recording is mandatory for interpretative accuracy and a time lapse is required before ABGs are measured when FiO2 is changed. This is particularly important in diseases with ventilation/perfusion mismatch such as COPD. Many guidelines recommend allowing 30 minutes for time to steady state in severe COPD, although only 10–16 minutes are required after a change in FiO2 to accurately record PaO2. There is much clinical value in promptly recording and regularly monitoring ABGs in AECOPD.

CXR is useful for aiding diagnosis in AECOPD and identifying co-morbidities. It is necessary to exclude other causes of dyspnoea, such as pulmonary oedema, pneumonia or pneumothorax. Additionally, COPD is responsible for 50–70% of secondary spontaneous pneumothorax cases, so identifying a possible pneumothorax is important. Patients with COPD are twice as likely to have venous thromboembolic events as those without COPD. The prevalence of pulmonary embolism (PE) in patients suspected of AECOPD is 11.3%. Patients with AECOPD are at increased risk of heart failure and a standardised approach for evaluating CXRs is superior at predicting two-year mortality than a routine approach. CXR can reliably detect cardiomegaly on a postero-anterior (PA) film. However, AECOPD patients in the ED will receive a portable anteroposterior (AP) CXR. A reliable corrected cardiothoracic ratio (CTR) for AP CXRs can be calculated using a previous PA CXR. CXRs at presentation of AECOPD have a range of important clinical applications and can highlight co-morbidities that may otherwise be undetected.

ECGs are commonly used in emergency departments and can identify cardiac co-morbidity in AECOPD. A predisposing factor for relapse
in AECOPD is poor cardiovascular investigation and care. Identifying co-morbid patients and managing them appropriately may reduce this.\(^{(22)}\) ECG detected 37% prevalence of heart disease (HD) in hospitalised AECOPD patients.\(^{(23,24)}\) ECG is also an important tool for ruling out other causes of acute dyspnoea such as myocardial infarction and serious arrhythmias.\(^{(7)}\) Therefore, its place in the initial investigations of AECOPD is well founded.

FBC can identify an infective aetiology of AECOPD, and U&Es are a marker of renal function to aid safe pharmaceutical prescribing.\(^{(7)}\) However, leucocytosis may correlate poorly with bacterial pneumonia.\(^{(25)}\) Erythrocyte count can detect anaemia as an alternative cause for dyspnoea or detect polycythaemia secondary to chronic hypoxia in COPD.\(^{(26)}\) Serum urea recorded at presentation can predict inpatient mortality in AECOPD. Those with urea exceeding 7.35 mmol/L had 23.4% mortality risk, compared with an overall inpatient mortality of 15.5%.\(^{(27)}\) FBC and U&Es are useful for baseline measurements and monitoring. They may support a diagnosis but should not be solely relied upon.

Blood cultures are indicated in pyrexial patients with AECOPD, although pyrexia only shows a trend towards the likelihood of blood culture testing positive, and 13% of bacteraemia cases are in afebrile patients.\(^{(28)}\) Reports suggest pyrexia is not a significant predictor for positive blood culture, and positive blood cultures are not well utilised for guiding focused treatment.\(^{(29)}\) Suspicion of bacteraemia should therefore encompass other clinical factors. This is reinforced by the lack of a universal definition of pyrexia.

Patients on theophylline therapy at presentation must have blood levels measured to avoid potential toxicity in case the drug is prescribed.\(^{(30)}\)

**Aims**

To investigate whether practice in the ED of a small island community in the British Isles is in line with UK best-practice guidelines for the initial management and investigations in AECOPD. This is measured through a retrospective audit of clinical records. Recommendations for improvement are made with consideration of potential barriers.

**Methods**

An algorithm returned a list of patients who met the criteria ‘adult ED attendances’ AND ‘arrival date and time’, AND any of:

- diagnosis description OR free text contains ‘COPD’
- diagnosis description OR free text contains ‘COAD’ (chronic obstructive airway disease)
diagnosis free text contains ‘emphys’
• diagnosis free text contains ‘bronchit’.

This supplied 65 patients from the four-month period September 2013–January 2014. The patients’ physical ED clinical records were individually inspected and patients were included if the diagnosis was coded as ‘exacerbation of COPD’ or if a diagnosis of ‘exacerbation of COPD’ was written in the medical notes. A total of 19 patients were excluded due to absence of COPD diagnosis or coding error, 6 were excluded due to failure to locate clinical records. The final audit sample included 40 patients (Figure 1). The clinical records were analysed using a data collection tool.

Results

The main results are summarised in Table 1.

Table 1: Main audit results

<table>
<thead>
<tr>
<th>Audit standard</th>
<th>Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nebulised pharmaceutical therapy must be prescribed driven by compressed air, not oxygen</td>
<td>0%</td>
</tr>
<tr>
<td>All patients must receive ABGs with the FiO2 noted</td>
<td>47.5%</td>
</tr>
<tr>
<td>All patients must receive a chest X ray (CXR)</td>
<td>97.5%</td>
</tr>
<tr>
<td>All patients must receive an ECG</td>
<td>92.5%</td>
</tr>
<tr>
<td>All patients must receive an FBC and U&amp;Es</td>
<td>95%</td>
</tr>
<tr>
<td>Pyrexial patients must have blood cultures taken</td>
<td>100%</td>
</tr>
<tr>
<td>Patients on theophylline must have levels recorded at admission</td>
<td>0%</td>
</tr>
</tbody>
</table>
Discussion

Standard 1: nebulised pharmaceutical therapy
The guidance that air-driven nebulisers should be used is clearly relevant to the ED as 34 (85%) patients received nebulisers (Figure 2). Compliance to this standard is subject to the availability of compressed air. The ED clinical notes for each patient have a designated prescription chart where the driving gas can be specified. None of the patients who received nebulised pharmaceutical therapy had the driving gas documented here. A total of 3 patients received oxygen-driven nebulisers and 1 patient received air-driven nebulisers, as documented in the written clinical notes (Figure 2). Therefore, in the remaining 30 cases the driving gas could not be determined.

Consequently, it is difficult to comment on the true compliance with the guideline. The audit did not collate data from any pre-hospital nebulised therapy that may have been administered. This may have influenced the decision to prescribe nebulisers in the ED, although the audit standard does not state that all patients must receive nebulisers. It can be inferred that there was 0% compliance with the standard that the driving gas should be specified in the prescription.

Standards 2–5: ABG, CXR, ECG, FBC, U&Es
The ED has a near-point ABG analysis machine and the data entry menu permits input of the FiO₂ value. A fifth of patients did not have ABG, and of those who did only 19 (60%) had the FiO₂ noted (Figure 3), implying that 40% of ABGs were vulnerable to inaccurate interpretation. In those

![Figure 2: Patients who received nebulisers driven by air.](image-url)

Patients who received nebulisers, n = 34 (85%). Driving gas of patients who received nebulisers, air: n = 1 (2.9%), oxygen: n = 3 (8.8%), not documented: n = 30 (88.2%). Driving gas was not documented in the prescription chart.
who did not receive ABG there was no documented evidence of substitution by venous blood sampling.

Patients who received ABG had the analysis printout present with written confirmation in the clinical notes, whereas the remaining eight patients had neither. Some patients received more than one ABG, but the regularity of measurements was difficult to assess as the timestamp was often worn. The FiO2 was sometimes included in the data input but often written on the printout by hand; therefore, it is uncertain when this was recorded. A vital-signs chart including administered oxygen therapy was mostly present in the notes, but times did not always correlate with ABG measurements so this was not reliable for determining the FiO2. Additional investigations carried out in patients who did not have an ABG, including CXR, FBC and U&E, are shown in Figure 4. These are included in the discussion as it may be postulated that ABGs were omitted as they are more invasive.

Whilst five of the eight patients received all the other investigations, the
remaining three had at least one missing. ECG was missing in two patients and CXR was missing in one patient. Both patients lacking ECG did have CXR, despite CXR requiring a request from the radiology department and involving exposure to ionising radiation. ECG is relatively safer and easier to carry out and would therefore be expected in these patients. Two patients were lacking FBC and U&Es even though CXR or ECG had been carried out, suggesting abnormalities were at least suspected and therefore supportive laboratory analysis and monitoring was indicated.

Figure 5 demonstrates the number of patients from the whole sample who received the four mandatory investigations in the ED. The findings do not account for the possibility that absent investigations were carried out following admission to a ward. The audit standards do not specify time constraints for investigations as this does not form part of the guidelines.

One patient did not have a CXR despite receiving nebulised pharmaceutical therapy, which suggests that there was clinical suspicion of a respiratory cause for presentation. ABG was also absent, indicating there may have been inadequate monitoring of markers of respiratory function. FBC and U&Es were not documented in the notes despite an unconfirmed aetiology of AECOPD and pharmaceutical management being initiated.

Several CXR reports remarked that the CTR could not be commented on due to the AP CXR, indicating that cardiomegaly was unlikely to be detected in these patients based on CXR findings alone.

ECG is readily available in the ED and can be operated by lower grade staff without specialist training, although interpretation must be performed by a doctor. Three patients did not have an ECG (see Figure 5),

![Figure 5](image-url)

**Figure 5: Patients who received investigations in the ED.**

Patients who had ABG, $n = 32$ (80%). Patients who had CXR, $n = 39$ (97.5%). Patients who had ECG, $n = 37$ (92.5%). Patients who had FBC and U&E, $n = 38$ (95%).
of which none were pyrexic and two did not receive nebulisers, suggesting that a cardiac presentation requiring ECG assessment should have been considered. Furthermore, all three patients had CXR, highlighting that there may have been a missed opportunity to identify cardiac co-morbidity that cannot be determined by AP CXR. The audit did not analyse the findings from the ECGs; therefore, the prevalence of co-morbidities that may predispose patients to relapse is beyond the scope of this study.

FBC and U&Es are frequently ordered in the ED and can be authorised by any doctor. Two patients did not receive these investigations, both of whom were afebrile and received either CXR or ECG, implying that a respiratory or cardiac presentation was considered more likely than a condition of infective aetiology. All patients who did receive FBC and U&Es had at least one other mandatory investigation, so these laboratory investigations were never solely relied upon.

**Standard 6: blood cultures from pyrexic patients**

Measurement of temperature is a simple clinical skill which forms an integral part of basic observations in the ED and pre-hospital care. Four (10%) patients in the audit were pyrexic, all of whom received blood cultures (figure 6), as well as CXR, ECG, and FBC and U&Es. Therefore, compliance with the audit standard was 100%, although the small sample size may question the significance of this finding.

The study did not account for patients who may have received anti-pyretics before observations were taken, which may in some cases lead to the omission of blood cultures in patients presenting with an infective aetiology. A significant weakness of this aspect of the audit was the lack

**Figure 6:** Patients who were pyrexic and had blood cultures.

Patients who were pyrexic, \( n = 4 \) (10%). Patients who were pyrexic and had blood cultures, \( n = 4 \) (100%).
of a quantitative definition of pyrexia in the audit standards. To overcome this, an arbitrary figure of 38.0°C was used. Unless the ED implements its own definition of pyrexia then individual cases are exposed to subjective interpretation. Furthermore, the study did not analyse whether afebrile patients received blood cultures.

**Standard 7: recording of theophylline levels on admission**

Drug histories are handwritten in the ED clinical notes, included as a photocopy or omitted. Theophylline levels can be analysed from the serum-separating tube (SST) available in the ED. Only two patients (5%) were recorded as being on theophylline therapy. Both received nebulisers and ABG, implying the presence of respiratory distress, yet neither had theophylline levels measured.

However, there is only a small potential risk of theophylline toxicity if intravenous methylxanthines are prescribed. There was no evidence from the clinical documentation that patients were exposed to this risk. Drug history was often omitted, so the true number of patients on theophylline is unknown. Patients who were on theophylline had the drug history included as a photocopy of the repeat prescription, so there was no sign that this drug was specifically acknowledged.

**Conclusions**

The ED could improve its clinical practice in the initial management and investigations of AECOPD. More research needs to be carried out into the use of nebulised pharmaceutical therapy in the ED. The carrying out of basic investigations is generally good, although there are some issues with adequate documentation. Protocols should be put in place to follow up underlying co-morbidities appropriately. Indications for blood culture could be clarified further to reduce bias from subjective interpretation. Awareness should be raised surrounding the potential risks of theophylline toxicity. Re-audit should be conducted and the audit standards should be adhered to for all patients presenting with AECOPD. Specific recommendations and potential barriers are described in Table 2.

**References**


Table 2: Recommendations from the audit and potential barriers to change

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Potential barrier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nebulisers should have the driving gas specified in the prescription chart of the ED notes</td>
<td>Lack of awareness</td>
</tr>
<tr>
<td>The FiO₂ should be entered into the ABG analysis data input form</td>
<td>Lack of awareness; assumption that it is not necessary</td>
</tr>
<tr>
<td>A protocol should be implemented for follow-up of co-morbidities in primary or secondary care, with a possible risk stratification for relapse</td>
<td>Ambiguity as to who is responsible; requires time and research; low detection rates of co-morbidities</td>
</tr>
<tr>
<td>Criteria for blood cultures should be implemented, with consideration of the definition of pyrexia</td>
<td>May conflict with hospital sepsis guidelines; requires time and research; may conflict with clinical judgement</td>
</tr>
<tr>
<td>All patients should have their theophylline status in the drug history of the ED notes</td>
<td>Lack of awareness; information may not be available</td>
</tr>
</tbody>
</table>


9 Bronchodilators; COPD. In: Joint Formulary Committee, British National Formulary, 67th ed [Internet]. London: British Medical


